Isomorphic Labs, the AI drug-discovery company spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital as it seeks to take its drug candidates into clinical trials, TechCrunch reported.[1] The company announced on Nov. 17 that it had closed the round, according to SiliconANGLE.[2]
Small Molecule News reported that Lilly paid $45 million upfront and Novartis paid $37.5 million upfront, which it said together is $82.5 million in committed partner cash against $7.7 billion of equity.[3] Small Molecule News said the pipeline is still preclinical.[3] No regulator has yet approved an AI-designed drug, Bloomberg noted, according to TNW.[4]
The company's product, the Isomorphic Labs Drug Design Engine, or IsoDDE, uses AI to speed up several of the tasks involved in developing new medicines, SiliconANGLE reported.[2] SiliconANGLE reported that IsoDDE skips the step of freezing a target protein in a crystal and scanning it with specialized X-ray equipment to create the 3D protein models that FEP, a method the pharmaceutical industry uses to search for binding mechanisms, often requires.[2]
Thrive Capital led a $600 million round in March 2025 and a $2.1 billion Series B on May 12, 2026, Small Molecule News reported, and outside funding now stands at $7.7 billion across three rounds in under 20 months.[3] The round is the company's first since chief executive Demis Hassabis stepped back as Google DeepMind's chief executive in August, TNW reported; he is now DeepMind's chair and Alphabet's chief scientist.[4]
Sequoia partner Konstantine Buhler told Bloomberg the firm backed Isomorphic because it has found scaling laws for its models, meaning performance keeps improving with more computing power and data, TNW reported.[4] Isomorphic did not disclose its valuation, TechCrunch reported, though Bloomberg had reported earlier this month that the company was looking to raise at a $50 billion valuation.[1]